Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)Cohort Study · 2014 · 426 citations
2Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerCohort Study · 2015 · 2,907 citations
3Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocolsRCT · 2017 · 91 citations
4Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyRandomized Controlled Trial · 2017 · 1,801 citations
5Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialRandomized Controlled Trial · 2015 · 1,983 citations

More from The Lancet Oncology

More from University College London